JP5497006B2 - 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 - Google Patents

膵管腺癌の検出および治療のためのプレクチン−１標的化剤 Download PDF

Info

Publication number
JP5497006B2
JP5497006B2 JP2011505127A JP2011505127A JP5497006B2 JP 5497006 B2 JP5497006 B2 JP 5497006B2 JP 2011505127 A JP2011505127 A JP 2011505127A JP 2011505127 A JP2011505127 A JP 2011505127A JP 5497006 B2 JP5497006 B2 JP 5497006B2
Authority
JP
Japan
Prior art keywords
peptide
cancer
cells
cell
pdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011505127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521897A (ja
JP2011521897A5 (enExample
Inventor
ケリー、キンバリー
ワイスリーダー、ラルフ
バーディーシー、ナビール
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2011521897A publication Critical patent/JP2011521897A/ja
Publication of JP2011521897A5 publication Critical patent/JP2011521897A5/ja
Application granted granted Critical
Publication of JP5497006B2 publication Critical patent/JP5497006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2011505127A 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 Active JP5497006B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4481808P 2008-04-14 2008-04-14
US61/044,818 2008-04-14
PCT/US2009/040480 WO2009129220A2 (en) 2008-04-14 2009-04-14 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014042379A Division JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Publications (3)

Publication Number Publication Date
JP2011521897A JP2011521897A (ja) 2011-07-28
JP2011521897A5 JP2011521897A5 (enExample) 2012-07-05
JP5497006B2 true JP5497006B2 (ja) 2014-05-21

Family

ID=41199683

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011505127A Active JP5497006B2 (ja) 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Country Status (6)

Country Link
US (4) US8829159B2 (enExample)
EP (2) EP2862871A1 (enExample)
JP (3) JP5497006B2 (enExample)
CA (1) CA2758415C (enExample)
HK (1) HK1209438A1 (enExample)
WO (1) WO2009129220A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129220A2 (en) * 2008-04-14 2009-10-22 The Gereral Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
JP2013510094A (ja) * 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
DE102010039289A1 (de) * 2010-08-12 2012-02-16 Leica Microsystems (Schweiz) Ag Mikroskopsystem
US10174361B2 (en) * 2011-11-10 2019-01-08 Exosome Diagnostics, Inc. Cerebrospinal fluid assay
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
US10860526B2 (en) * 2012-12-01 2020-12-08 The Regents Of The University Of California System and method of managing large data files
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
WO2015017506A2 (en) * 2013-07-30 2015-02-05 Blend Therapeutics, Inc. Nanoparticle diagnostic and methods for treating disease
US10182791B2 (en) * 2013-10-07 2019-01-22 The Regents Of The University Of California Integrated ultrasound, OCT, PA and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts
EP3378937B1 (en) * 2015-11-19 2021-06-09 Niigata University Peptide having accumulation specific to pancreatic cancer, and use of said peptide
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
JP7197078B2 (ja) * 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
JP2019534285A (ja) * 2016-10-26 2019-11-28 カオ グループ、インク． 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
CN112105380A (zh) * 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
CA3081925A1 (en) * 2017-11-18 2019-05-23 Nzola DE MAGALHAES Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
US11890352B2 (en) 2018-02-27 2024-02-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
US20220026432A1 (en) * 2018-12-14 2022-01-27 Konica Minolta, Inc. Method for forecasting arrival of drug inside diseased tissue
CN114814200B (zh) * 2022-05-09 2025-06-27 浙江大学 一种纳米颗粒-荧光标记融合蛋白复合体及其单链dna检测方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
WO1985003508A1 (en) 1984-02-08 1985-08-15 Cetus Corporation Toxin conjugates
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
PL310897A1 (en) 1993-03-29 1996-01-08 Univ Cincinnati Analogues of yy peptide and their application
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US5968479A (en) 1995-01-30 1999-10-19 Daiichi Pure Chemicals Co., Ltd. Diagnostic marker
US20030100051A1 (en) * 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US20030103975A1 (en) * 1999-11-03 2003-06-05 Jones Jonathan C.R. Modulation of angiogenesis and endothelialization
US20030069180A1 (en) * 2000-06-09 2003-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AUPR290801A0 (en) * 2001-02-06 2001-03-01 Peter Maccallum Cancer Institute, The Substrate binding domain
WO2002098364A2 (en) * 2001-06-06 2002-12-12 The General Hospital Corporation Magnetic-nanoparticle conjugates and methods of use
WO2003030725A2 (en) * 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20050249668A1 (en) * 2002-03-29 2005-11-10 Ralph Weissleder Nir-fluorescent cyanine dyes, their synthesis and biological use
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
EP1756165A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
EP2005187A4 (en) * 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
KR20100074177A (ko) 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 미토콘드리아-표적화된 항-종양 물질
WO2009129220A2 (en) * 2008-04-14 2009-10-22 The Gereral Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
CA2745307A1 (en) * 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions

Also Published As

Publication number Publication date
EP2265630B1 (en) 2014-10-29
US20110182814A1 (en) 2011-07-28
JP2014132021A (ja) 2014-07-17
JP2011521897A (ja) 2011-07-28
HK1209438A1 (en) 2016-04-01
US20190209715A1 (en) 2019-07-11
US20150151010A1 (en) 2015-06-04
EP2265630A2 (en) 2010-12-29
US20170087257A1 (en) 2017-03-30
JP2017048239A (ja) 2017-03-09
JP6046070B2 (ja) 2016-12-14
WO2009129220A3 (en) 2010-01-21
US8829159B2 (en) 2014-09-09
EP2862871A1 (en) 2015-04-22
CA2758415A1 (en) 2009-10-22
CA2758415C (en) 2019-06-04
EP2265630A4 (en) 2012-12-12
US10124077B2 (en) 2018-11-13
WO2009129220A2 (en) 2009-10-22
US9387265B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
JP5497006B2 (ja) 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
Sugahara et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors
JP6684857B2 (ja) ダイナミックｂｈ３プロファイリング
US12458618B2 (en) Compounds and methods for the detection of TRPV-6 cancers and drug delivery
TWI494566B (zh) 膀胱癌特異性配體肽
von Spreckelsen et al. Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican
Pung et al. Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
US9486545B2 (en) Method of screening for colon cancer using biomarkers
CN107868129B (zh) 与肝癌标志物gpc3相关的亲和肽
KR20210039078A (ko) 위암의 복강 전이 진단용 펩타이드 프로브
Ma et al. Screening of an annexin‐A2‐targeted heptapeptide for pancreatic adenocarcinoma localization
US9581598B2 (en) Diagnosis and treatment of brain tumor
HK1169661B (en) Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
HK1169661A (en) Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140305

R150 Certificate of patent or registration of utility model

Ref document number: 5497006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250